|
1
|
The National Board of Health and Welfare
(Socialstyrelsen). Nationella riktlinjer för bröst-, prostata-,
tjocktarms- och ändtarmscancervård. 2013. ISBN:
978-91-7555-038-12013-2-29 (in Swedish).
|
|
2
|
Sieh W, Lichtensztajn DY, Nelson DO, et
al: Treatment and mortality in men with localized prostate cancer:
a population-based study in California. Open Prost Cancer J. 6:1–9.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stattin P, Johansson R, Lodnert R, et al:
Geographical variation in incidence of prostate cancer in Sweden.
Scand J Urol Nephrol. 39:372–379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carter HB: American Urological Association
(AUA) guideline on prostate cancer detection: process and
rationale. BJU Int. 112:543–547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kelloff GJ, Choyke P and Coffey DS;
Prostate Cancer Imaging Working Group. Challenges in clinical
prostate cancer: role of imaging. Am J Roentgenol. 192:1455–1470.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Widmark A, Klepp O, Solberg A, et al:
Endocrine treatment, with or without radiotherapy, in locally
advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase
III trial. Lancet. 373:301–308. 2009. View Article : Google Scholar
|
|
7
|
Tannock IF, de Wit R, Berry WR, et al:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. New Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petrylak DP, Tangen CM, Hussain MH, et al:
Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. New Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pienta KJ and Bradley D: Mechanisms
underlying the development of androgen-independent prostate cancer.
Clin Cancer Res. 12:1665–1671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Signoretti S, Montironi R, Manola J, et
al: Her-2-neu expression and progression toward androgen
independence in human prostate cancer. J Natl Cancer Inst.
92:1918–1925. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Craft N, Shostak Y, Carey M and Sawyers
CL: A mechanism for hormone-independent prostate cancer through
modulation of androgen receptor signaling by the HER-2/neu tyrosine
kinase. Nat Med. 5:280–285. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Culig Z, Hobisch A, Cronauer MV, et al:
Androgen receptor activation in prostatic tumor cell lines by
insulin-like growth factor-I, keratinocyte growth factor, and
epidermal growth factor. Cancer Res. 54:5474–5478. 1994.
|
|
13
|
Minner S, Jessen B, Stiedenroth L, et al:
Low level HER2 overexpression is associated with rapid tumor cell
proliferation and poor prognosis in prostate cancer. Clin Cancer
Res. 16:1553–1560. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
So A, Gleave M, Hurtado-Col A and Nelson
C: Mechanisms of the development of androgen independence in
prostate cancer. World J Urol. 23:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bacus SS, Altomare DA, Lyass L, et al:
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers
and may contribute to tumor aggressiveness by enhancing cell
survival. Oncogene. 21:3532–3540. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hynes NE and Lane HA: ERBB receptors and
cancer: the complexity of targeted inhibitors. Nat Rev Cancer.
5:341–354. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vacchelli E, Aranda F, Eggermont A, et al:
Trial Watch: Tumor-targeting monoclonal antibodies in cancer
therapy. Oncoimmunology. 3:e270482014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sharma PS, Sharma R and Tyagi T: Receptor
tyrosine kinase inhibitors as potent weapons in war against
cancers. Curr Pharm Des. 15:758–776. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Altai M, Orlova A and Tolmachev V:
Radiolabeled probes targeting tyrosine-kinase receptors for
personalized medicine. Review invited. Curr Pharm Des.
20:2275–2292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Albanell J, Codony J, Rovira A, Mellado B
and Gascón P: Mechanism of action of anti-HER2 monoclonal
antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med
Biol. 532:253–268. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
The US National Institutes of Health.
Evaluation of carboplatin/paclitaxel with and without trastuzumab
(Herceptin) in uterine serous cancer. ClinicalTrials.gov.
NCT01367002, 2014-2-13. http://clinicaltrials.gov/ct2/show/NCT01367002?term=NCT01367002&rank=1.
|
|
23
|
The US National Institutes of Health.
Safety study of 212Pb-TCMC-trastuzumab radio
immunotherapy. ClinicalTrials.gov. NCT01384253, 2014-2-13.
http://clinicaltrials.gov/show/NCT01384253.
|
|
24
|
The US National Institutes of Health.
Paclitaxel and radiation therapy with or without trastuzumab in
treating patients who have undergone surgery for bladder cancer.
ClinicalTrials.gov. NCT00238420, 2014-2-13. http://clinicaltrials.gov/ct2/show/study/NCT00238420.
|
|
25
|
Zuehlke A and Johnson JL: Hsp90 and
co-chaperones twist the functions of diverse client proteins.
Biopolymers. 93:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wheeler DL, Huang S, Kruser TJ, et al:
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB)
family members. Oncogene. 27:3944–3956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malmberg J, Tolmachev V and Orlova A:
Imaging agents for in vivo molecular profiling of disseminated
prostate cancer: Cellular processing of [(111)In]-labeled
CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate
cancer cell lines. Exp Ther Med. 2:523–528. 2011.
|
|
28
|
Malmberg J, Tolmachev V and Orlova A:
Imaging agents for in vivo molecular profiling of
disseminated prostate cancer targeting EGFR receptors in prostate
cancer: Comparison of cellular processing of
[111In]-labeled affibody molecule ZEGFR:2377
and cetuximab. Int J Oncol. 38:1137–1143. 2011.
|
|
29
|
Ahlgren S, Orlova A, Wållberg H, et al:
Targeting of HER2-expressing tumors using 111In-ABY-025, a
second-generation affibody molecule with a fundamentally
reengineered scaffold. J Nucl Med. 51:1131–1138. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Baek KH, Hong ME, Jung YY, et al:
Correlation of AR, EGFR, and HER2 expression levels in prostate
cancer: Immunohistochemical analysis and chromogenic in situ
hybridization. Cancer Res Treat. 44:50–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Carrion-Salip D, Panosa C, Menendez JA, et
al: Androgen-independent prostate cancer cells circumvent EGFR
inhibition by overexpression of alternative HER receptors and
ligands. Int J Oncol. 41:1128–1138. 2012.PubMed/NCBI
|
|
32
|
Malmberg J, Perols A, Varasteh Z, et al:
Comparative evaluation of synthetic anti-HER2 Affibody molecules
site-specifically labelled with 111In using N-terminal
DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer
xenografts. Eur J Nucl Med Mol Imaging. 39:481–492. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wållberg H, Orlova A, Altai M, et al:
Molecular design and optimization of 99mTc-labeled recombinant
affibody molecules improves their biodistribution and imaging
properties. J Nucl Med. 52:461–469. 2011.PubMed/NCBI
|
|
34
|
Baum RP, Prasad V, Müller D, et al:
Molecular imaging of HER2-expressing malignant tumors in breast
cancer patients using synthetic 111In- or 68Ga-labeled
Affibody molecules. J Nucl Med. 51:892–897. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sörensen J, Sandberg D, Sandström M, et
al: First-in-human molecular imaging of HER2 expression in breast
cancer metastases using the 111In-ABY-025 Affibody
molecule. J Nucl Med. 55:730–735. 2014.PubMed/NCBI
|
|
36
|
Kramer-Marek G, Kiesewetter DO and Capala
J: Changes in HER2 expression in breast cancer xenografts after
therapy can be quantified using PET and (18)F-labeled affibody
molecules. J Nucl Med. 50:1131–1139. 2009. View Article : Google Scholar
|
|
37
|
Clinic H: Hallwang Clinic Treatments.
2014-2-13. http://www.germancancertreatments.com/treatments-at-hallwang-clinic/.
|
|
38
|
Andersson K: Bringing time into molecular
and cellular biology. J Anal Oncol. 2:652013.
|
|
39
|
Pacey S, Wilson RH, Walton M, et al: A
phase I study of the heat shock protein 90 inhibitor alvespimycin
(17-DMAG) given intravenously to patients with advanced solid
tumors. Clin Cancer Res. 17:1561–1570. 2011. View Article : Google Scholar : PubMed/NCBI
|
